Yildirim C
Mol Biol Rep. 2024; 51(1):571.
PMID: 38662155
DOI: 10.1007/s11033-024-09563-w.
Oyama T, Yasunaga M, Jona M, Nishikawa M, Yatomi Y, Honda A
J Clin Exp Hematop. 2023; 63(3):187-192.
PMID: 37635085
PMC: 10628828.
DOI: 10.3960/jslrt.23023.
Nikitin E, Kislova M, Morozov D, Belyakova V, Suvorova A, Sveshnikova J
Leukemia. 2023; 37(7):1464-1473.
PMID: 37202442
PMC: 10195665.
DOI: 10.1038/s41375-023-01891-3.
Khan S, Allsup D, Molica S
Front Oncol. 2023; 13:1135812.
PMID: 37091176
PMC: 10117948.
DOI: 10.3389/fonc.2023.1135812.
Gamal W, Sahakian E, Pinilla-Ibarz J
Blood Adv. 2022; 7(11):2401-2417.
PMID: 36574293
PMC: 10238851.
DOI: 10.1182/bloodadvances.2022008985.
Effects of ibrutinib on T-cell immunity in patients with chronic lymphocytic leukemia.
Liu Y, Song Y, Yin Q
Front Immunol. 2022; 13:962552.
PMID: 36059445
PMC: 9437578.
DOI: 10.3389/fimmu.2022.962552.
Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B-cell lymphoma.
Daniel A, Ghez D, Ravaiau C, Cavalieri D, Tournilhac O, Herbaux C
Eur J Haematol. 2022; 109(6):719-727.
PMID: 36048142
PMC: 9826375.
DOI: 10.1111/ejh.13858.
Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies.
Maharaj K, Uriepero A, Sahakian E, Pinilla-Ibarz J
Front Immunol. 2022; 13:943354.
PMID: 35979372
PMC: 9376239.
DOI: 10.3389/fimmu.2022.943354.
Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with Chronic Lymphocytic Leukemia.
Vitale C, Boccellato E, Comba L, Jones R, Perutelli F, Griggio V
Cancers (Basel). 2021; 13(15).
PMID: 34359757
PMC: 8345723.
DOI: 10.3390/cancers13153856.
Prognostic Value of Tie2-Expressing Monocytes in Chronic Lymphocytic Leukemia Patients.
Wos J, Chocholska S, Kowalska W, Tomczak W, Szymanska A, Karczmarczyk A
Cancers (Basel). 2021; 13(11).
PMID: 34198760
PMC: 8200999.
DOI: 10.3390/cancers13112817.
Revisiting Autoimmunity in Chronic Lymphocytic Leukemia: Prognostic Value of Positive Direct Antiglobulin Test in a Retrospective Study and Literature Review.
Ahmed S, Abdallah G, Aly M, Abdelsalam E, Mohammed Saleh M
J Blood Med. 2021; 12:225-234.
PMID: 33880072
PMC: 8053514.
DOI: 10.2147/JBM.S296225.
Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia.
Griggio V, Perutelli F, Salvetti C, Boccellato E, Boccadoro M, Vitale C
Front Immunol. 2020; 11:594556.
PMID: 33312177
PMC: 7708380.
DOI: 10.3389/fimmu.2020.594556.
Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies.
Kikushige Y
J Clin Exp Hematop. 2020; 60(4):146-158.
PMID: 33148933
PMC: 7810248.
DOI: 10.3960/jslrt.20036.
Autoimmune Cytopenias in Chronic Lymphocytic Leukemia: Focus on Molecular Aspects.
Fattizzo B, Barcellini W
Front Oncol. 2020; 9:1435.
PMID: 31998632
PMC: 6967408.
DOI: 10.3389/fonc.2019.01435.
Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL.
Mhibik M, Wiestner A, Sun C
Int J Mol Sci. 2019; 21(1).
PMID: 31861854
PMC: 6981459.
DOI: 10.3390/ijms21010068.
Molecular Interactions Between Innate and Adaptive Immune Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications.
Haseeb M, Anwar M, Choi S
Front Immunol. 2018; 9:2720.
PMID: 30542344
PMC: 6277854.
DOI: 10.3389/fimmu.2018.02720.
Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre.
Hampel P, Larson M, Kabat B, Call T, Ding W, Kenderian S
Br J Haematol. 2018; 183(3):421-427.
PMID: 30117139
PMC: 6234062.
DOI: 10.1111/bjh.15545.
[Prognostic significance of Treg/Th17 cells imbalance in patients with diffuse large B cell lymphoma].
Zhu M, Wan W, Tian L, Hu K, Wang J, Wang Y
Zhonghua Xue Ye Xue Za Zhi. 2018; 39(6):507-510.
PMID: 30032570
PMC: 7342911.
DOI: 10.3760/cma.j.issn.0253-2727.2018.06.014.
Emerging role of BCR signaling inhibitors in immunomodulation of chronic lymphocytic leukemia.
Maharaj K, Sahakian E, Pinilla-Ibarz J
Blood Adv. 2018; 1(21):1867-1875.
PMID: 29296833
PMC: 5728096.
DOI: 10.1182/bloodadvances.2017006809.
Imbalance in circulatory iNKT, Th17 and T regulatory cell frequencies in patients with B-cell non-Hodgkin's lymphoma.
Hus I, Bojarska-Junak A, Kaminska M, Dobrzynska-Rutkowska A, Szatan K, Szymczyk A
Oncol Lett. 2017; 14(6):7957-7964.
PMID: 29250184
PMC: 5727614.
DOI: 10.3892/ol.2017.7232.